Greg Friberg

Vice President, Medical Affairs for Europe, Latin America, Middle East, Africa, and Canada (the ELMAC Region), Amgen

Greg currently serves as Vice President, Medical Affairs for Europe, Latin America, Middle East, Africa, and Canada (the ELMAC Region), having taken on the role in the Summer of 2021.

Greg joined Amgen in Medical Sciences in 2006, first serving as an early development lead and then as Oncology Therapeutic Area (TA) head for the early pipeline. Starting in 2014, Greg served as the interim Global Development co-TA head for Oncology, overseeing the initial regulatory approvals for blinatumomab and talimogene laherparepvec. Greg then served for two years as Global Product General Manager for blinatumomab and the early hematology BiTE portfolio. Starting in 2018, Greg became the Global Development TA Head for Hematology/Oncology and Bone. He helped build the development team over the next 4 years and to usher romosozumab, blinatumomab for MRD, and sotorasib to their first approvals. Of note, sotorasib was the first KRAS G12C inhibitor approved in the US, with under three years from first patient dosed to FDA approval.

Greg received his A.B. from Middlebury College and M.D. from New York Medical College. He completed his residency in internal medicine at Dartmouth-Hitchcock Medical Center and his fellowship in hematology and oncology at The University of Chicago Medical Center. He joined the faculty of the University of Chicago thereafter as a member of the Phase I, Gastrointestinal, and Gynecologic oncology teams and an investigator for early phase clinical trials.

Updated: March 2022